25 March 2020
Botanix announces top line BTX 1204 atopic dermatitis data
• BTX 1204 did not achieve statistical significance in the primary and secondary endpoints in its
Phase 2 atopic dermatitis study
• Botanix will be finalising a comprehensive review of the study data and will provide an update
on the BTX 1204 program and its broader dermatology platform
Philadelphia PA and Sydney Australia, 25 March 2020: Clinical stage synthetic cannabinoid company
Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or “the Company”) today announced that BTX
1204 did not meet the primary endpoint in its Phase 2 study evaluating the safety and efficacy in
patients with moderate atopic dermatitis (“1204 Study”).
Sad
25 March 2020Botanix announces top line BTX 1204 atopic...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
-0.010(3.57%) |
Mkt cap ! $425.2M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.0¢ | 26.8¢ | $2.645M | 9.461M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 1008444 | 26.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 24999 | 1 |
View Market Depth
| Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
27.0¢ |
Change
-0.010 ( 3.91 %) |
||||
| Open | High | Low | Volume | ||
| 28.8¢ | 29.0¢ | 26.5¢ | 5418297 | ||
| Last updated 15.59pm 14/05/2024 ? | |||||
| BOT (ASX) Chart |